Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

September 27, 2022

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

August 30, 2022

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 25, 2022

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

Events

Sep 12, 2022
7:00 AM EDT

Aclaris Therapeutics, Inc. at H.C. Wainwright 24th Annual Global Investment Conference

Jun 8, 2022
11:30 AM EDT

Aclaris Therapeutics, Inc. at Jefferies Healthcare Conference

May 24, 2022
7:00 AM EDT

Aclaris Therapeutics, Inc. at H.C. Wainwright Global Investment Conference

Feature Presentation

Aclaris Therapeutics Company Overview - August 2022

Aclaris Therapeutics Company Overview - August 2022

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2022 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.